Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TransCon hGH vs Daily hGH in Chinese Pediatric GHD
NCT04326374Phase 3Unknown
- Sponsor
- VISEN Pharmaceuticals
- Start
- Dec 2019
- Primary completion
- Apr 2022
- Modality
- Recombinant Proteins and Enzymes, Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lonapegsomatropin in growth hormone deficiency (GHD), sponsored by VISEN Pharmaceuticals. Status: unknown.
02
Drugs
lonapegsomatropin
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT04326374.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04326374.